Eledon Pharmaceuticals Inc (ELDN) USD0.001
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines for persons living with an autoimmune disease, which requires an organ or cell-based transplant or living with amyotrophic lateral sclerosis (ALS). The Company's lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb) designed to target CD40 Ligand (CD40L) also called CD154), a molecule expressed on the surface of human immune system T cells. The central role of CD40 or CD40L signaling in generating pro-inflammatory responses makes it a candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance and neuroinflammation. Blocking the activation of the CD40L pathway prevents acute and long-term allograft transplant rejection in multiple animal species and ameliorates disease progression and pathology in preclinical models of autoimmunity and ALS.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.